BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28472910)

  • 1. Helix-Coil Transition Signatures B-Raf V600E Mutation and Virtual Screening for Inhibitors Directed Against Mutant B-Raf.
    Bandaru S; Sumithnath TG; Sharda S; Lakhotia S; Sharma A; Jain A; Hussain T; Nayarisseri A; Singh SK
    Curr Drug Metab; 2017 Jul; 18(6):527-534. PubMed ID: 28472910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer.
    Yao H; Sun Q; Zhu J
    Arch Pharm (Weinheim); 2016 Oct; 349(10):808-815. PubMed ID: 27624806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docking-based structural splicing and reassembly strategy to develop novel deazapurine derivatives as potent B-Raf
    Wang GM; Wang X; Zhu JM; Guo BB; Yang Z; Xu ZJ; Li B; Wang HY; Meng LH; Zhu WL; Ding J
    Acta Pharmacol Sin; 2017 Jul; 38(7):1059-1068. PubMed ID: 28414204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Purinylpyridinylamino-based DFG-in/αC-helix-out B-Raf inhibitors: Applying mutant versus wild-type B-Raf selectivity indices for compound profiling.
    Liu L; Lee MR; Kim JL; Whittington DA; Bregman H; Hua Z; Lewis RT; Martin MW; Nishimura N; Potashman M; Yang K; Yi S; Vaida KR; Epstein LF; Babij C; Fernando M; Carnahan J; Norman MH
    Bioorg Med Chem; 2016 May; 24(10):2215-34. PubMed ID: 27085672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structural optimization of imidazothiazole derivatives affords a new promising series as B-Raf V600E inhibitors; synthesis, in vitro assay and in silico screening.
    Ammar UM; Abdel-Maksoud MS; Ali EMH; Mersal KI; Ho Yoo K; Oh CH
    Bioorg Chem; 2020 Jul; 100():103967. PubMed ID: 32470760
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In silico identification of novel kinase inhibitors by targeting B-Raf(v660e) from natural products database.
    Wang ZJ; Wan ZN; Chen XD; Wu CF; Gao GL; Liu R; Shi Z; Bao JK
    J Mol Model; 2015 Apr; 21(4):102. PubMed ID: 25832798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and discovery of thioether and nicotinamide containing sorafenib analogues as multikinase inhibitors targeting B-Raf, B-Raf
    Sun S; He Z; Huang M; Wang N; He Z; Kong X; Yao J
    Bioorg Med Chem; 2018 May; 26(9):2381-2391. PubMed ID: 29631788
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer.
    Okimoto RA; Lin L; Olivas V; Chan E; Markegard E; Rymar A; Neel D; Chen X; Hemmati G; Bollag G; Bivona TG
    Proc Natl Acad Sci U S A; 2016 Nov; 113(47):13456-13461. PubMed ID: 27834212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel natural inhibitors targeting B-RAF(V600E) by computational study.
    Wu B; Zhang Z; Dou G; Lv X; Ge J; Wang H; Xie H; Zhu D
    Bioengineered; 2021 Dec; 12(1):2970-2983. PubMed ID: 34252351
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Design of potent B-Raf
    Wang ZF; Wang PF; Ma JT; Chai YZ; Hu HM; Gao WL; Wang ZC; Wang BZ; Zhu HL
    Chem Biol Drug Des; 2018 Feb; 91(2):567-574. PubMed ID: 29045039
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
    Zhang Q; Zhang X; You Q
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Electrostatic mechanism of V600E mutation-induced B-Raf constitutive activation in colorectal cancer: molecular implications for the selectivity difference between type-I and type-II inhibitors.
    Liu T; Wang Z; Guo P; Ding N
    Eur Biophys J; 2019 Jan; 48(1):73-82. PubMed ID: 30218115
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Insight into molecular dynamics simulation of BRAF(V600E) and potent novel inhibitors for malignant melanoma.
    Tang HC; Chen YC
    Int J Nanomedicine; 2015; 10():3131-46. PubMed ID: 25960652
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Limited Proteolysis Combined with Stable Isotope Labeling Reveals Conformational Changes in Protein (Pseudo)kinases upon Binding Small Molecules.
    Di Michele M; Stes E; Vandermarliere E; Arora R; Astorga-Wells J; Vandenbussche J; van Heerde E; Zubarev R; Bonnet P; Linders JT; Jacoby E; Brehmer D; Martens L; Gevaert K
    J Proteome Res; 2015 Oct; 14(10):4179-93. PubMed ID: 26293246
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
    Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
    [No Abstract]   [Full Text] [Related]  

  • 17. Molecular insight into mutation-induced conformational change in metastasic bowel cancer BRAF kinase domain and its implications for selective inhibitor design.
    Zhao K; Zhou X; Ding M
    J Mol Graph Model; 2018 Jan; 79():59-64. PubMed ID: 29145034
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rational design, synthesis, and biological evaluation of Pan-Raf inhibitors to overcome resistance.
    Wang L; Zhu G; Zhang Q; Duan C; Zhang Y; Zhang Z; Zhou Y; Lu T; Tang W
    Org Biomol Chem; 2017 Apr; 15(16):3455-3465. PubMed ID: 28368067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and biological evaluation of novel benzo-α-pyrone containing piperazine derivatives as potential BRAF
    Chen LW; Wang ZF; Zhu B; Man RJ; Liu YD; Zhang YH; Wang BZ; Wang ZC; Zhu HL
    Bioorg Med Chem Lett; 2016 Oct; 26(20):4983-4991. PubMed ID: 27634195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of potential inhibitors targeting BRAF-V600E mutant melanoma cells.
    Kadioglu O; Saeed MEM; Greten HJ; Mayr K; Schrama D; Roos WP; Efferth T
    J Am Acad Dermatol; 2021 Apr; 84(4):1086-1089. PubMed ID: 32707252
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.